semaglutide en france will cover the costs of weight-loss drugs from 15 June, according to the country's health minister. ➡️ https://l.euronews.com/RPCh semaglutide en france Novo Nordisk

If you're denied, you still have options

For example, a patient consuming 90 grams of protein daily may benefit more from dividing intake into three 30-gram meals rather than consuming a light breakfast and lunch followed by a large protein-rich dinner

That window is not endless

never skip escalation steps [6]

Several firms have already licensed their drugs to US or European drugmakers like AstraZeneca and Merck & Co for further clinical development outside the country

However, despite their effectiveness, GLP-1 agonists are not without drawbackshigh cost, gastrointestinal side effects, long-term dependency, and concerns about sustainability once the drug is discontinued